SPOTLIGHT: Rival drug drives QLT stock lower

Analysts downgraded QLT, which makes Visudyne, the dominant drug for age-related macular degeneration, after Genentech reported impressive results from clinical trials of its new treatment for the disease, Lucentis. QLT's stock dropped to a 52-week low as the news hit the market. The stock closed at $11.75, down $1.07, after touching a new low of $11.62 early in the session. It was quoted at $21 in January. Article

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.